Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28951024 | 0.86 | — | — | |
| Hydrazine SCHEMBL1996202 | 0.83 | — | — | |
| Ethyne SCHEMBL27795216 | 0.83 | — | — | |
| Hydrazine SCHEMBL1013687 | 0.81 | AHR (0.54) | AHRESR1ESR2CYP1B1ALDH1A1 | |
| SCHEMBL27996566 | 0.79 | AHR (0.52) | AHRESR1ESR2CYP1B1ALDH1A1 | |
| Bicarbonate SCHEMBL575081 | 0.78 | AHR (0.46) | AHRALDH1A1CYP3A4TSHRTP53 | |
| Acetic Acid SCHEMBL28517501 | 0.78 | AHR (0.46) | AHRALDH1A1TSHRTP53PTGER1 | |
| SCHEMBL10353413 | 0.77 | AHR (0.50) | AHRESR1ESR2CYP1B1ALDH1A1 | |
| Ethylamine SCHEMBL28458525 | 0.75 | AHR (0.48) | AHRCYP1B1ALDH1A1CYP3A4TSHR | |
| SCHEMBL29171599 | 0.70 | APP (0.48) | ESR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088776-A | Method for preparing 2-nitrobiphenyl compound | 江西天宇化工有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-111201624-A | Organic light emitting diode | 株式会社LG化学 | 2020-05-26 | — | — | CN | disclosed |
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| CN-109476599-A | Guanidine derivatives and its medical usage | 东丽株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-109476647-A | The pyrimidine compound of weeding | 巴斯夫欧洲公司 | 2019-03-15 | — | — | CN | disclosed |
| US-9296696-B2 | Aryl derivatives and uses thereof | JACOBUS PHARMACEUTICALS COMPANY, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2917200-A1 | ARYL DERIVATIVES AND USES THEREOF | Jacobus Pharmaceutical Company, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150080324-A1 | Aryl Derivatives And Uses Thereof | JACOBUS PHARMACEUTICAL COMPANY INC (US) | 2015-03-19 | — | — | US | disclosed |
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6677338-B2 | FOR THERAPY OF DEPRESSION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-13 | — | — | US | disclosed |
| US-20030105096-A1 | Serotonin transport inhibitors | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | MALT1, GUCY1A1, GUCY1B1 | AHR 3245/4885ESR1 4479/4885ESR2 4064/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | AHR 1237/4885ESR1 3040/4885ESR2 2859/4885 |
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | AHR 109/4885ESR1 793/4885ESR2 402/4885 |
| US-20150080324-A1 | Aryl Derivatives And Uses Thereof | G6PD, ABCC1, ABL1 | AHR 202/4885ESR1 4688/4885ESR2 4188/4885 |
| US-10662156-B2 | Guanidine derivative and medical use thereof | MALT1, GUCY1A1, GUCY1B1 | AHR 3245/4885ESR1 4479/4885ESR2 4064/4885 |
| US-20030105096-A1 | Serotonin transport inhibitors | SLC6A4, SLC6A2, SLC18A2 | AHR 1315/4885ESR1 2623/4885ESR2 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.